What drove Stryker's revenue growth in 1993?

Growth came mainly from unit volume, which accounted for the entire 17% increase, as pricing added only about 1%. Surgical products rose 13%, led by the High Vacuum Cement Injection System, the Surgilav Plus irrigation system, Osteonics knee implants, and the 3-Chip Camera. Medical products surged 33%, driven by the MPS Primary Acute Care Bed and physical therapy services.

Is Stryker's profitability improving?

Yes. Operating margin rose to 16.5% from 15.4%, and net margin rose to 10.8% from 10.0%. Cost of sales fell as a percentage of sales due to cost reduction programs and a higher mix of international sales, and SG&A dropped to 30.9% of sales from 31.3%. The effective tax rate also declined to 37.3% from 38.0%.

What risks does the filing identify for investors?

The filing cites uncertainty over U.S. health care reform, which has slowed domestic medical device sales; hospital purchasers shifting toward lower-cost orthopaedic implants; and government cost-containment proposals whose long-term effects cannot be predicted. Customer concentration is also a factor, since Matsumoto accounted for 12% of sales. Foreign currency movements offset price gains in 1993, and the company relies on single sources for certain purchased materials.

Why did Stryker's debt increase, and what is the Matsumoto investment?

Long-term debt rose to $31.3 million from $1.4 million, primarily from a five-year yen-denominated bank loan at a fixed 4.9% rate, maturing in 1998. The loan financed the August 1993 purchase of 20% of Matsumoto Medical Instruments, Inc. in Osaka for about $33 million. The investment is accounted for under the equity method, and Matsumoto's 1993 earnings contribution was immaterial.

What is Stryker's R&D spending and product pipeline?

R&D, development and engineering expense rose 12% to $36.2 million, or 6.5% of sales. Key 1993 launches included the MPS Primary Acute Care Bed, the Quadracut ACL/Shaver arthroscopy system, the Surgilav Plus pulsed irrigation system, and the Series 7000 modular and posterior-stabilized knee components. The company is also running clinical trials of its Osteogenic Protein Device, which began in 1992 and compares its efficacy with autografts for non-union fractures.

SYK 10-K FY1993 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 24, 1994. Cited figures are marked; the original filing is the authoritative source.

Stryker Corporation (NASDAQ: STRY) closed 1993 with strong top-line and earnings growth.

Net sales rose 17% to $557.3 million^a from $477.1 million, and net earnings increased 26% to $60.2 million, or $1.25 per share, from $47.7 million ($1.00). Operating margin widened to 16.5% from 15.4%, driven by a lower cost of sales (46.1% of sales vs. 46.5%) and SG&A that fell to 30.9% of sales from 31.3%. Growth was led by Surgical products (orthopaedic implants, endoscopy, powered instruments), which rose 13% to $447.0 million, while Medical products (specialty stretchers/beds and physical therapy) jumped 33% to $110.3 million.

International sales reached 32% of total revenue, and domestic sales grew 14% despite headwinds from U.S. health care reform uncertainty and purchaser shifts toward lower-cost implants. Balance sheet strengthened meaningfully. Cash and marketable securities totaled $152.6 million at year-end, and working capital rose to $214.0 million^b.

Stockholders' equity grew to $288.4 million^c, and return on average equity held at 23.1%. The company took on $31.3 million in long-term debt, mostly a five-year yen-denominated loan used to finance a 20% stake in Japanese distributor Matsumoto Medical Instruments (about $33 million, accounted for under the equity method). Inventory days improved to 114 from 130, and receivable days fell to 47 from 52, indicating better working capital management.

Operating cash flow was $86.1 million^d, up from $50.7 million. For investors, the key points are consistent double-digit growth, expanding margins, and a healthy balance sheet, offset by dependence on the orthopaedic segment, exposure to health care cost-containment policy, and a sizable 12% of sales tied to a single customer (Matsumoto). The company also continued to invest heavily in R&D, which rose 12% to $36.2 million.

02—Key points

Key Highlights

Net sales grew 17% to $557.3 million; Surgical products contributed 80% of revenue and Medical products 20%.
Net earnings rose 26% to $60.2 million, or $1.25 per fully diluted share, with net margin improving to 10.8% from 10.0%.
Operating income increased 25% to $91.9 million, with operating margin expanding to 16.5% from 15.4%.
International sales reached 32% of total revenue, with Osteonics and Dimso spinal implants leading growth abroad.
Cash and marketable securities of $152.6 million and working capital of $214.0 million provide substantial financial flexibility.
Operating cash flow reached $86.1 million, up sharply from $50.7 million in 1992.
Matsumoto Medical Instruments, Japan's exclusive distributor, accounted for 12% of net sales ($64.3 million), creating meaningful customer concentration.

03—Questions

Frequently Asked Questions

What drove Stryker's revenue growth in 1993?
Growth came mainly from unit volume, which accounted for the entire 17% increase, as pricing added only about 1%. Surgical products rose 13%, led by the High Vacuum Cement Injection System, the Surgilav Plus irrigation system, Osteonics knee implants, and the 3-Chip Camera. Medical products surged 33%, driven by the MPS Primary Acute Care Bed and physical therapy services.
Is Stryker's profitability improving?
Yes. Operating margin rose to 16.5% from 15.4%, and net margin rose to 10.8% from 10.0%. Cost of sales fell as a percentage of sales due to cost reduction programs and a higher mix of international sales, and SG&A dropped to 30.9% of sales from 31.3%. The effective tax rate also declined to 37.3% from 38.0%.
What risks does the filing identify for investors?
The filing cites uncertainty over U.S. health care reform, which has slowed domestic medical device sales; hospital purchasers shifting toward lower-cost orthopaedic implants; and government cost-containment proposals whose long-term effects cannot be predicted. Customer concentration is also a factor, since Matsumoto accounted for 12% of sales. Foreign currency movements offset price gains in 1993, and the company relies on single sources for certain purchased materials.
Why did Stryker's debt increase, and what is the Matsumoto investment?
Long-term debt rose to $31.3 million from $1.4 million, primarily from a five-year yen-denominated bank loan at a fixed 4.9% rate, maturing in 1998. The loan financed the August 1993 purchase of 20% of Matsumoto Medical Instruments, Inc. in Osaka for about $33 million. The investment is accounted for under the equity method, and Matsumoto's 1993 earnings contribution was immaterial.
What is Stryker's R&D spending and product pipeline?
R&D, development and engineering expense rose 12% to $36.2 million, or 6.5% of sales. Key 1993 launches included the MPS Primary Acute Care Bed, the Quadracut ACL/Shaver arthroscopy system, the Surgilav Plus pulsed irrigation system, and the Series 7000 modular and posterior-stabilized knee components. The company is also running clinical trials of its Osteogenic Protein Device, which began in 1992 and compares its efficacy with autografts for non-union fractures.

04—Continue

← View all 10-K filings